What is William Blair’s Estimate for LENZ FY2026 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for LENZ Therapeutics in a research note issued to investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings of ($2.89) per share for the year. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share.

LENZ has been the subject of a number of other research reports. Citigroup lifted their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen began coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $41.67.

LENZ Therapeutics Price Performance

NASDAQ:LENZ opened at $26.49 on Friday. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93. The company has a market cap of $728.50 million, a PE ratio of -5.55 and a beta of 0.58. The firm has a 50-day moving average of $24.15 and a 200-day moving average of $27.06.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of LENZ Therapeutics by 5.3% in the 4th quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock worth $34,022,000 after buying an additional 59,630 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in LENZ Therapeutics by 83.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company’s stock worth $23,760,000 after acquiring an additional 374,326 shares during the period. Paradigm Biocapital Advisors LP bought a new stake in LENZ Therapeutics during the fourth quarter worth $22,243,000. State Street Corp boosted its position in LENZ Therapeutics by 18.7% in the third quarter. State Street Corp now owns 289,154 shares of the company’s stock worth $6,865,000 after purchasing an additional 45,600 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its stake in LENZ Therapeutics by 16.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company’s stock valued at $4,103,000 after purchasing an additional 20,000 shares during the period. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.